Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350001, China.
Fujian Abdominal Surgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350001, China.
Cell Death Dis. 2023 Mar 28;14(3):221. doi: 10.1038/s41419-023-05715-1.
The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3. In situ fluorescence hybridization was conducted to localize the cellular distribution of METTL3 and DEAD-box helicase 23 (DDX23). CCK8, colony formation, EDU incorporation, TUNEL, wound healing and Transwell assays were carried out accordingly to study the viability, proliferation, apoptosis, and mobility of cells under different treatments in vitro. Xenograft and animal lung metastasis experiments were also conducted to study the functional role of METTL3 or DDX23 on tumor growth and lung metastasis in vivo. MeRIP-qPCR and bioinformatical analyses were used to obtain the potential direct targets of METTL3. It was shown that m6A methyltransferase METTL3 was upregulated in PDAC tissues with gemcitabine resistance, and its knockdown sensitized pancreatic cancer cells to chemotherapy. Furthermore, silencing METTL3 remarkably reduced pancreatic cancer cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, validation experiments confirmed that DDX23 mRNA was a direct target of METTL3 in YTHDF1-dependent manner. Additionally, DDX23 silence resulted in the suppression of pancreatic cancer cell malignancy and PIAK/Akt signaling inactivation. Strikingly, rescuse experiments demonstrated the inhibitive effects of METTL3 silence on cell phenotypes and gemcitabine resistance were partially reversed by forcibly expressed DDX23. In summary, METTL3 promotes PDAC progression and gemcitabine resistance by modifying DDX23 mRNA m6A methylation and enhancing PI3K/Akt signaling activation. Our findings establish a potential tumor promotive and chemo-resistant role for METTL3/DDX23 axis in PDAC.
本研究旨在阐明 METTL3 通过其下游靶 mRNA 的 m6A 修饰及其信号通路来调节胰腺导管腺癌 (PDAC) 进展的机制。采用免疫印迹和 qRT-PCR 检测 METTL3 的表达水平。采用原位荧光杂交技术定位 METTL3 和 DEAD 框解旋酶 23 (DDX23) 的细胞分布。相应地进行 CCK8、集落形成、EDU 掺入、TUNEL、划痕愈合和 Transwell 测定,以研究不同处理条件下细胞在体外的活力、增殖、凋亡和迁移。还进行了异种移植和动物肺转移实验,以研究 METTL3 或 DDX23 在体内肿瘤生长和肺转移中的功能作用。MeRIP-qPCR 和生物信息学分析用于获得 METTL3 的潜在直接靶标。结果表明,在具有吉西他滨耐药性的 PDAC 组织中,m6A 甲基转移酶 METTL3 上调,其敲低使胰腺癌细胞对化疗敏感。此外,沉默 METTL3 可显著减少胰腺癌细胞在体外和体内的增殖、迁移和侵袭。机制验证实验证实,DDX23 mRNA 是 METTL3 在 YTHDF1 依赖性方式下的直接靶标。此外,沉默 DDX23 导致胰腺癌细胞恶性程度降低,PIAK/Akt 信号失活。引人注目的是,挽救实验表明,METTL3 沉默对细胞表型的抑制作用和对吉西他滨耐药性的部分逆转可通过强制表达 DDX23 来逆转。总之,METTL3 通过修饰 DDX23 mRNA m6A 甲基化和增强 PI3K/Akt 信号激活来促进 PDAC 的进展和吉西他滨耐药性。我们的研究结果确立了 METTL3/DDX23 轴在 PDAC 中具有潜在的肿瘤促进和化疗耐药作用。